The São Paulo Court blocked R $ 33 million to fund the treatment of a 7 -year -old
The decision was issued on February 11, and may appeal it.
The medication for this rare syndrome costs around R $ 17 million – the final treatment, the excess value should be returned to Bradesco Saúde.
The plan had refused to provide the Elevidys remedy, a single dose injection that acts as a genetic therapy, on the grounds that medication was not part of the ANS (National Health Agency) list and had excessively high cost.
The decision may open precedents for patients who need Elevidys.
Viviane Guimarães, the patient’s lawyer, said that health plans cannot deny coverage to treatments considered essential for survival and quality of life.
“This sentence inaugurates a new understanding of the responsibility of health plans and can benefit other patients in similar situations,” says Viviane.
In a statement, Bradesco Saúde says that “does not comment on cases taken to the judiciary.”
Gift Link: Did you like this text? Subscriber can release seven free hits from any link per day. Just click on F Blue below.
Your signature can be further
Do you already know the advantages of being a subscriber of Folha? In addition to having access to reports and columns, you have exclusive newsletters (). You can also download our free app from or to receive alerts from the main news of the day. Your signature helps us do independent and quality journalism. Thanks!
Your signature is worth a lot
More than 180 reports and analyzes published every day. A team with over 200 columnists and bloggers. Professional journalism that supervises the government, conveys profitable and inspiring news, opposes the intolerance of social networks and traces a clear line between truth and lie. How much does it cost to help produce this content?
